

## PerkinElmer expands computing capabilities for biological drug discovery

22 March 2021 | News

**Through its propriety Signals <sup>™</sup> platform enables Interfaces with Geneious Prime and SnapGene software will help significantly reduce research cycle times and accelerate biologics and vaccine development**



PerkinElmer, Inc., has announced that its [Signals <sup>™</sup> computing](#) platform for documentation, workflow and decision making is expanding to take advantage of existing capabilities in the biological drug discovery area. This breakthrough comes from collaboration with [Insightful Science](#), a software company focused on the global life sciences community.

Through this alliance, pharmaceutical and academic research teams can unite the power of the PerkinElmer Signals <sup>™</sup> platform with leading solutions from Insightful Science's bioinformatics division. This includes the popular [SnapGene](#) and [Geneious Prime](#) software offerings that help molecular biologists design and execute DNA construct design, molecular cloning, and other types of molecular biology research. The integration will offer scientists the ability to access and compare data between experiments and instruments and collaborate more intuitively. They will also be able to replicate trials and experiments instantly, allowing for faster results and more informed decisions about drug and vaccine targets.

"There is limited availability of computing tools in the biologics space," said Kevin Willoe, vice president and general manager of PerkinElmer's IT division. "Through our collaboration with Insightful Science, we are able to provide enhanced computing capabilities to scientists conducting vital research on biologics and vaccines. This will help significantly reduce cycle times for researchers and help them make data-driven decisions. faster and more accurately - important capabilities when fighting enemies like cancer, cardiovascular, neurological and viral diseases," he adds.

"Integrating the best scientific software with cloud-based data platforms is increasingly important for modern pharmaceutical and biotech companies to streamline research and ensure the integrity of valuable data," says Brett Amundsen, CEO of Bioinformatics, Insightful Science. "The combination of SnapGene and Geneious Prime software with the PerkinElmer Signals platform dramatically improves research workflows and enriches collaboration. In this way, scientists can better connect with their ideas and data, so they can focus on producing life-changing results," he concludes.